大行評級丨高盛:上調京東健康目標價至42.5港元 上調收入及盈利預測
高盛發表報告指,京東健康首季收入和利潤超出預期,主要受惠藥品和營養產品強勁勢頭及毛利率擴張。該行重申對京東健康領先地位的信心,基於公司在在線醫療健康行業的強大供應鏈能力和用戶中的品牌知名度。管理層考慮到下半年投資力度較大,對今年維持較保守指引,即收入雙位數增長及營運利潤按年基本持平。但該行預測高於市場共識和公司指引,基於該行相信京東健康將在藥品類別中擴大市佔,並受惠實時需求的流量增長。該行上調對京東健康今年至2027年收入預測平均2%,反映主要由藥品和營養產品支撐的銷售表現強於預期,並將同期淨利潤預測上調1%至3%。該行對該股目標價由37.8港元上調至42.5港元,評級“買入”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.